Novartis Cosentyx® OKd as first intravenous (IV) formulation interleukin-17A antagonist for rheumatic diseases

 

• First new intravenous (IV) treatment option in six years for adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA)^1-6
• Cosentyx^® (secukinumab) administered via IV infusion offers healthcare providers choice and flexibility to tailor treatment to their patients' unique needs
• With both IV and subcutaneous formulations, Cosentyx can now help a broader range of PsA, AS and nr-axSpA patients manage their condition

https://www.biospace.com/article/releases/fda-approves-novartis-cosentyx-as-first-intravenous-iv-formulation-interleukin-17a-antagonist-for-rheumatic-diseases/